RANK-RANKL-OPG信号通路在骨重建中的分子作用机制

doi:10.13701/j.cnki.kqyxyj.2016.06.027

摘要/Abstract

摘要： 骨是动态的活性组织,通过由骨吸收和骨形成所组成的骨重建来维持自身的平衡及结构的完整性。核因子kB受体活化因子--kB受体活化因子配体--骨保护蛋白通路是骨吸收和骨形成发生耦联的关键通路,其对于维持骨重建的平衡、成骨细胞的分化以及调控破骨细胞生成等过程起着重要的作用。此外,此通路的深入研究对于骨质疏松症、心血管疾病的临床治疗具有重要的指导意义。本文就RANK-RANKL-OPG信号通路在骨发生和吸收中的分子作用机制作一综述。

关键词: 核因子kB受体活化因子, kB受体活化因子配体, 骨保护素, 骨重建, 破骨细胞

Abstract: Bone is a dynamic organization which sustains its balance and structural integrity through bone remodeling that composed of bone resorption and bone formation. Receptor activator of nuclear factor kB (RANK)-receptor activator of nuclear factor kB ligand (RANKL)-osteoprotegerin (OPG) has major effects on bone remodeling, especially in the osteoblast lineage to regulate the differentiation and activity of osteoclasts. In addition, the further research of this pathway will have important guiding significance for the clinical treatment of osteoporosis and cardiovascular disease. This article aims to explain the RANK-RANKL-OPG signaling pathway's molecular mechanism in bone.

中图分类号:

R782.12

李雪 ,周延民 ,马珊珊 ,马遥 ,郭天奇 ,徐昭南. RANK-RANKL-OPG信号通路在骨重建中的分子作用机制[J]. 口腔医学研究, 2016, 32(6): 659-671.

LI Xue, ZHOU Yan-min, MA Shan-shan, MA Yao, GUO Tian-qi, XU Zhao-nan.. Role of RANK-RANKL-OPG Signaling Pathway in Bone Remodeling[J]. Journal of Oral Science Research, 2016, 32(6): 659-671.

参考文献

[1] Parfitt AM. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression [J]. Bone, 2002, 30(1)∶5-7
[2] Aubin JE.Advances in the osteoblast lineage [J]. Biochem Cell Bio, 1998, 76(6)∶899-910
[3] Singh PP, van der Kraan AG, Xu J,et al.Membrane-bound receptor activator of NFκB ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factors [J]. Biochem Biophys Res Commun, 2012, 422(1)∶48-53
[4] Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling [J]. Arch Biochem Biophys,2008,473(2)∶139-46
[5] Simonet WS, Lacey DL, Dunstan CR,et al.Osteoprotegerin: a novel secreted protein involved in the regulation of bonedensity [J]. Cell,1997,89(2)∶309-19
[6] Anderson DM, Maraskovsky E, Billingsley WL,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J]. Nature, 1997, 390(6656)∶175-79
[7] Kanazawa K, Kudo A. Self-assembled RANK induces osteoclastogenesis ligand-independently [J]. J Bone Miner Res,2005,20(11)∶2053-60
[8] Darnay BG, Haridas V, Ni J, et al. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase [J]. J Biol Chem, 1998, 273(32)∶20551-5
[9] Wong BR, Josien R, Lee SY,et al. TRANCE (tumor necrosis factor [TNF] -related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor [J]. J Exp Med, 1997, 186(12)∶2075-80
[10] Silva I, Branco JC. Rank/Rankl/opg: literature review [J]. Acta Reumatol Port,2011,36(3)∶209-18
[11] Boyce BF. Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts [J]. J Bone Miner Res,2013 ,28(4)∶711-22
[12] Che W, Dong Y, Quan HB. RANKL inhibits cell proliferation by regulating MALAT1 expression in a human osteoblastic cell line hFOB 1.19 [J]. Cell Mol Biol (Noisy-le-grand),2015,61(1)∶7-14
[13] Yasuda H. RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases [J]. World J Orthop,2013 ,4(4)∶207-17
[14] Abdelmagid SM, Sondag GR, Moussa FM, et al.Mutation in Osteoactivin Promotes RANKL-Mediated Osteoclast Differentiation and Survival, but Inhibits Osteoclast Function [J]. J Biol Chem,2015,Apr 2.pii:jbc.M114.624270 [Epub ahead of print] PubMed PMID:25837253
[15] Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin:paracrine regulators of bone metabolism and vascular function [J]. Arterioscle Thromb Vasc Biol, 2002 ,22(4)∶549-53
[16] Simonet WS, Lacey DL, Dunstan CR,et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [J]. Cell,1997,89(2)∶309-19
[17] Yamaguchi K, Kinosaki M, Goto M,et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor [J]. J Biol Chem, 1998, 273(9)∶5117-23
[18] Théoleyre S, Kwan Tat S, Vusio P,et al. Characterization of osteoprotegerinbinding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK [J]. Biochem Biophys Res Commun, 2006, 347(2)∶460-7
[19] Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function [J]. Arterioscler Thromb Vasc Biol,2002,22(4)∶549-53
[20] Bjerre M. Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications [J]. Springerplus,2013,2,658
[21] Boyce BF, Xiu Y, Li J,et al. NF-κB-Mediated Regulation of Osteoclastogenesis [J]. Endocrinol Metab (Seoul),2015,30(1)∶35-44
[22] Xing L, Chen D, Boyce BF. Mice Deficient in NF-kappaB p50 and p52 or RANK Have Defective Growth Plate Formation and Post-natal Dwarfism [J]. Bone Res,2013,4∶336-345
[23] Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond [J]. Front Immunol,2014,5∶511
[24] Martin TJ, Sims NA. RANKL/OPG; Critical role in bone physiology [J]. Rev Endocr Metab Disord, 2015. [Epub ahead of print] PubMed PMID:25557611
[25] Siar CH, Tsujigiwa H, Ishak I, et al. RANK, RANKL, and OPG in recurrent solid/multicystic ameloblastoma: their distribution patterns and biologic significance [J]. Oral Surg Oral Med Oral Pathol Oral Radiol,2015 ,119(1)∶83-91
[26] 孔祥鹤,牛银波,李宇华,等.OPG/RANK/RANKL系统与骨质疏松研究最新进展[J].生命科学研究,2011,15(01)∶80-85
[27] Wu PF, Tang JY, Li KH. RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects [J]. Tumour Biol,2015,36(2)∶495-501
[28] Tsushima H, Okazaki K, Ishihara K,et al.CCAAT/enhancer-binding protein β promotes receptor activator of nuclear factor-kappa-B ligand (RANKL) expression and osteoclast formation in the synovium in rheumatoid arthritis [J]. Arthritis Res Ther,2015,17∶31
[29] Poornima IG, Mackey RH, Buhari AM,et al.Relationship between circulating serum osteoprotegerin and total receptoractivator of nuclear κ-B ligand levels, triglycerides, and coronary calcificationin postmenopausal women [J]. Menopause,2014,21(7)∶702-10